COMPANY:

Hedera

"Hedera Dx...has unveiled a fully streamlined solution that allows hospitals to adopt liquid biopsy testing locally for their patients with minimal efforts. The solution is a combination of laboratory reagents and a software platform...The solution is called Hedera Profiling 2 ctDNA Test Panel and it integrates easily with the existing instrument infrastructure of a hospital lab. The test is built on actionability, in other words focusing on finding a potential treatment."

"Swiss cancer liquid biopsy startup Hedera Dx is hoping to fill an unmet need in the cancer sequencing market, offering hospitals and community oncology providers a blood-based sequencing test and interpretation tool that can be rapidly deployed and easily kept in compliance with evolving regulatory requirements."

"Swiss techbio company Hedera Dx...will be launching this fall a blood-based testing solution to profile cancer DNA circulating in the blood, helping patients access better treatments. To do this, the company has raised €14M in funding."